-
Drugs
-
Therapeutic Biologic Applications (BLA)
- Approval Information (Labels and Reviews)
- Letters to Industry, Healthcare Providers, and Clinical Investigators
- Prescription Drug User Fee Act (PDUFA) Billable Products (PDF) (updated March 2009)
- Recalls and Withdrawals
- Research Divisions and Investigators
- Safety Information
- Violative Advertising and Promotional Labeling Letters
- Frequently Asked Questions About Therapeutic Biological Products
- Important Addresses
- Investigational New Drug Applications
- Required Postmarketing Adverse Experience Information
- Advertising and Promotional Labeling
- Reports of Biologic Product Deviations
- Biologic License Applications (BLAs), BLA Supplements, Annual Reports on Postmarketing Studies, Postmarketing Study Final Reports, Postmarketing Study Correspondence, and Distribution Reports
The therapeutic biological products now under CDER's review include:
- Monoclonal antibodies for in-vivo use
- Cytokines, growth factors, enzymes, immunomodulators; and thrombolytics
- Proteins intended for therapeutic use that are extracted from animals or microorganisms, including recombinant versions of these products (except clotting factors)
- Other non-vaccine therapeutic immunotherapies
OFFICE OF DRUG EVALUATION I
RESPONSIBLE OFFICE/DIVISION INDICATION PRODUCT Division of Cardiovascular and Renal Products Renal Disorders Cardiology Disorders Arterial Vascular Disorders Activase [Alteplase]
Cathflo Activase [Alteplase]
ReoPro [Abciximab]
Retavase [Reteplase]
Streptase [Streptokinase]
TNKase [Tenecteplase]Division of Neurology Products Neurology Peripheral neuropathy (not intrinsically painful neuropathies) Avonex [Interferon beta-1a]
Betaseron [Interferon beta-1b]
Botox [Botulinum Toxin Type A]
Myobloc [Botulinum Toxin Type B]
Rebif [Interferon beta-1a]
Tysabri [Natalizumab]Division of Psychiatry Products -----------------
-----------------
OFFICE OF DRUG EVALUATION II
RESPONSIBLE OFFICE/DIVISION INDICATION PRODUCT Division of Metabolism and Endocrinology Products Endocrine
Bone related (osteoporosis, surgery and other bone repair)-----------------
Division of Pulmonary and Allergy Products Allergy
PulmonaryPulmozyme [Dornase alfa]
Xolair [Omalizumab]Division of Anesthesia, Analgesia and Rheumatology Products Rheumatology
Pain treatment (including peripheral neuropathies that are intrinsically painful)Enbrel [Etanercept]
Humira TM [Adalimumab]
Kineret [Anakinra]
Orencia [Abatacept]
Remicade [Infliximab]
OFFICE OF DRUG EVALUATION III
RESPONSIBLE OFFICE/DIVISION INDICATION PRODUCT Division of Reproductive and Urologic Products Urologic
Reproductive-----------------
Division of Gastroenterology Products Gastrointestinal (includes non-viral hepatic disorders) Genetic metabolic (inborn) disorders
Large volume parenteralsAldurazyme [Laronidase]
Fabrazyme [Agalsidase beta]
Naglazyme [Galsulfase]
Division of Dermatology and Dental Products Dental
DermatologyAlferon N Injection [Interferon alfa-n3]
Amevive [Alefacept]
Raptiva [Efalizumab]
Regranex [Becaplermin]
Santyl [Collagenase]
OFFICE OF ANTIMICROBIAL PRODUCTS
RESPONSIBLE OFFICE/DIVISION INDICATION PRODUCT Division of Anti-Infective and Ophthalmology Products Bacterial infectious disease Sepsis
OphthalmologyXigris [Drotrecogin alfa (activated)] Division of Special Pathogen and Transplant Products Solid organ transplant Immunodeficiency white cell disorders
Special pathogens (e.g., fungal, TB, Anthrax)Actimmune [Interferon gamma-1b]
Orthoclone [Muromonab-CD3]
Simulect [Basiliximab]
Zenapax [Daclizumab]
Division of Antiviral Products Viral infections, including viral hepatitis Copasys Copegus [Peginterferon alfa-2a]
Infergen [Interferon alfacon-1]
Intron A [Interferon alfa-2b]
Pegasys [Peginterferon alfa-2a]
Peg-Intron [Peginterferon alfa-2b]
Roferon-A [Interferon alfa-2a]
Synagis [Palivizumab]
OFFICE OF ONCOLOGY DRUG PRODUCTS
RESPONSIBLE OFFICE/DIVISION INDICATION PRODUCT Division of Drug Oncology Products All small molecule cancer treatments
Consolidated from many different divisions
Cancer Prevention-----------------
Division of Biologic Oncology Products Biologic cancer treatments Biologic cancer ancillary treatments
All biologics for GVHD (all cause transplants)Avastin [Bevacizumab]
Bexxar [Tositumomab]
Campath [Alemtuzumab]
Elitek [Rasburicase]
Elspar [Asparaginase]
Eribitux [Cetuximab]
Herceptin [Trastuzumab]
Kepivance [Palifermin]
Leukine [Sargramostim]
Neulasta [Pegfilgrastim]
Neumega [Oprelvekin]
Neupogen [Filgrastim]
Oncaspar [Pegaspargase]
Ontak [Denileukin diftitox]
Proleukin [Aldesleukin]
Rituxan [Rituximab]
Zevalin [Ibritumomab tiuxetan]Division of Medical Imaging and Hematology Products Diagnostic imaging Hematology
Venous vascular disordersAbbokinase [Urokinase]
Aranesp [Darbepoetin alfa]
CEA-Scan TM [Arcitumomab]
Epogen [Epoetin alfa]
NeutroSpec [Technetium fanolesomab]
Procrit [Epoetin alfa]
ProstaScint [Capromab Pendetide]
Verluma [Nofetumomab]
-
-